Tag Archives: biib

Biogen’s Big-Volume Plunge Marks End Of 5-Year Run

Biogen’s (BIIB) second-quarter earnings topped views, but its flagship drugs Tecfidera and Tysabri both missed sales expectations. That caused the biotech’s quarterly revenue growth to come in well below consensus estimates. The company also cut its full-year revenue guidance. Shares are plunging in giant volume in the stock market today, gapping down 18% to their lowest level in nearly eight months. The stock is now trading more than 30% off of

Biogen Plunges On Slashed Guidance; AbbVie Q2 Mixed

Big-cap biotech Biogen (BIIB) beat Q2 earnings estimates Friday, but it lowered its guidance and reported failure in a clinical trial, sending its stock plummeting. Meanwhile, big pharma AbbVie (ABBV) reported a steadier quarter and affirmed its guidance, but its stock was sliding after sales came up short. Biogen’s earnings, excluding one-time items, rose 21% over the year-earlier quarter to $4.22 a share, beating analysts’ consensus by 12 cents.

Biogen, Lilly Alzheimer’s Data Spark Street Debate

Shares of Biogen (BIIB) and Eli Lilly (LLY) were both moving as they reported data on their key drug candidates for Alzheimer’s disease Wednesday, while Wall Street debated the meaning of the results. Biogen’s aducanumab was the particular focus of attention. At the Alzheimer’s Association International Conference (AAIC), the company reported the effects of aducanumab on patients with mild or prodromal (i.e. even earlier than mild) Alzheimer’s